icon
icon 11630 SW 97 Street, Miami, Florida 33176, US

Tag: Glioblastoma

KAZIA RECOGNISES GBM AWARENESS DAY 2022 AS IT EXPANDS CLINICAL TRIAL ACTIVITY IN EUROPE AND US

Press Release

Sydney, 20 July 2022 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is lending its support to Glioblastoma (GBM) Awareness Day 2022 and remains firmly focused on developing a treatment that may help improve the […]

Read More>>

CURATIVE BIOTECHNOLOGY ANNOUNCES IMT504 LICENSE FOR DEVELOPMENT OF PROPRIETARY NEXT-GEN COVID-19 VACCINE

Press Release

License from Mid-Atlantic BioTherapeutics for IMT504 Broadens Scope of Initial License Beyond Treatment of Symptomatic Rabies Boca Raton, FL, October 7, 2021 – Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”) announced today that the Company has reached […]

Read More>>

Curative Biotechnology, Inc. Names Marc Drimer, CPA to Board of Directors

Press Release

Appointment of Independent Director and Chairman of Audit Committee Expands Financial Expertise on Board Boca Raton, FL, July 20, 2021 — Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development stage biomedical company focused on novel therapies […]

Read More>>

Curative Biotechnology, Inc. Announces Ticker Symbol Change to “CUBT” on OTC Markets

Press Release

Company Appoints Kapil Bharti, Ph.D., and Dimiter Dimitrov, Ph.D. to Scientific and Clinical Advisory Board Boca Raton, FL / iCrowd Newswire/ April 29, 2021 / Curative Biotechnology, Inc.  (OTC: CUBT) a development-stage biomedical company focused on novel therapies for rare diseases, announced today the […]

Read More>>

Connectyx Technologies Holdings Group, Inc. Announces Definitive Agreement with Mid-Atlantic BioTherapeutics, Inc. for Treatment of Symptomatic Rabies

Press Release

Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases, announced today the Company has signed a definitive agreement with Mid-Atlantic BioTherapeutics, Inc. (MABT) to acquire worldwide rights […]

Read More>>

Cookies & Privacy

By using this website, you agree to us using cookies to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
More Information